Elutia Inc. (NASDAQ:ELUT) Short Interest Update

Elutia Inc. (NASDAQ:ELUT) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 17,000 shares, an increase of 32.8% from the March 15th total of 12,800 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 21,200 shares, the short-interest ratio is presently 0.8 days.

Institutional Investors Weigh In On Elutia

A number of institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in Elutia by 175.7% during the second quarter. Renaissance Technologies LLC now owns 60,416 shares of the company’s stock valued at $143,000 after acquiring an additional 38,500 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Elutia by 393.0% during the 2nd quarter. Geode Capital Management LLC now owns 69,569 shares of the company’s stock worth $164,000 after buying an additional 55,457 shares during the period. Jane Street Group LLC acquired a new stake in shares of Elutia during the 1st quarter worth approximately $29,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Elutia in the 4th quarter valued at $1,062,000. 74.03% of the stock is owned by institutional investors.

Elutia Stock Down 1.6 %

Shares of Elutia stock opened at $2.99 on Friday. The stock has a market cap of $72.57 million, a price-to-earnings ratio of -1.42 and a beta of 0.51. Elutia has a twelve month low of $1.10 and a twelve month high of $4.19. The company’s fifty day moving average is $3.37 and its 200 day moving average is $2.54.

Elutia (NASDAQ:ELUT) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.66) EPS for the quarter. The business had revenue of $5.88 million during the quarter. As a group, equities analysts anticipate that Elutia will post -1.68 earnings per share for the current fiscal year.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.